Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease

Brain

Volumn 135, Issue 7, 2012, Pages 2058-2073

  Chu, Yaping ^a   Morfini, Gerardo A ^b   Langhamer, Lori B ^a   He, Yinzhen ^a   Brady, Scott T ^b   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Axonal neuropathies; Conventional kinesin; Cytoplasmic dynein; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CYTOPLASMIC DYNEIN; DOPAMINE; DYNEIN LIGHT CHAIN TCTEX TYPE 3; KINESIN; KINESIN LIGHT CHAIN 1; MOLECULAR MOTOR; MUTANT PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC SYSTEM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE FIBER TRANSPORT; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA;

EID: 84863188413     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws133     Document Type: Article

References (37)

1. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007; 25: 134-49. (Pubitemid 44765223)
2. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009; 35: 385-98.
3. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006; 494: 495-514. (Pubitemid 41790998)
4. Chu Y, Mickiewicz AL, Kordower JH. α-Synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis 2011; 41: 71-82.
5. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 2009; 29: 3365-73.
6. Cross DJ, Flexman JA, Anzai Y, Maravilla KR, Minoshima S. Age-related decrease in axonal transport measured by MR imaging in vivo. Neuroimage 2008; 39: 915-26.
7. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. [Review]. Neuron 2003; 39: 889-909. (Pubitemid 37130207)
8. Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, Paradis S, et al. Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 2006; 311: 1008-12. (Pubitemid 43271729)
9. Flavell SW, Kim TK, Gray JM, Harmin DA, Hemberg M, Hong EJ, et al. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron 2008; 60: 1022-38.
10. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 2008; 105: 763-8. (Pubitemid 351171782)
11. Gyoeva FK, Bybikova EM, Minin AA. An isoform of kinesin light chain specific for the Golgi complex. J Cell Sci 2000; 113: 2047-54. (Pubitemid 30386508)
12. Iseki E, Kato M, Marui W, Uéda K, Kosaka K. A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies. J Neurol Sci 2001; 185: 129-34. (Pubitemid 32318518)
13. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14: 467-75.
14. Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett 1999; 269: 13-6. (Pubitemid 29305690)
15. Jensen PH, Li JY, Dahlström A, Dotti CG. Axonal transport of synucleins is mediated by all rate components. Eur J Neurosci 1999; 11: 3369-76. (Pubitemid 29484233)
16. Kanaan NM, Kordower JH, Collier TJ. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol 2007; 502: 683-700. (Pubitemid 46732491)
17. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100: 2884-9. (Pubitemid 36297593)
18. Li W, Hoffman PN, Stirling W, Price DL, Lee MK. Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J Neurochem 2004; 88: 401-10. (Pubitemid 38084556)
19. Lo KW, Kogoy JM, Pfister KK. The DYNLT3 light chain directly links cytoplasmic dynein to a spindle checkpoint protein, Bub3. J Biol Chem 2007; 282: 11205-12. (Pubitemid 47100802)
20. Lykkebo S, Jensen PH. Alpha-synuclein and presynaptic function: implications for Parkinson's disease.[Review]. Neuromol Med 2002; 2: 115-29. (Pubitemid 37012500)
21. Madine J, Doig AJ, Middleton DA. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 2006; 45: 5783-92.
22. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 2010; 285: 2807-22.
23. Moran LB, Kösel S, Spitzer C, Schwaiger FW, Riess O, Kreutzberg GW, et al. Expression of alpha-synuclein in non-apoptotic, slowly degenerating facial motoneurones. J Neurocytol 2001; 30: 515-21.
24. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, et al. Axonal transport defects in neurodegenerative diseases. [Review]. J Neurosci 2009; 29: 12776-86.
25. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, et al. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci USA 2007; 104: 2442-47. (Pubitemid 46391416)
26. Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 1997; 146: 91-103. (Pubitemid 27319723)
27. Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, et al. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci 2005; 25: 10220-9. (Pubitemid 41636218)
28. Pfister KK, Benashski SE, Dillman JF III, Patel-King RS, King SM. Identification and molecular characterization of the p24 dynactin light chain. Cell Motil Cytoskeleton 1988; 41: 154-67.
29. Raff MC, Whitmore AV, Finn JT. Axonal self-destruction and neurodegeneration. [Review]. Science 2002; 296: 868-71.
30. Roy S, Zhang B, Lee VM, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. [Review]. Acta Neuropathol 2005; 109: 5-13. (Pubitemid 40287785)
31. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 2010; 30: 8083-95.
32. Serulle Y, Morfini G, Pigino G, Moreira JE, Sugimori M, Brady ST, et al. 1-Methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKCdelta enzymatic activities. Proc Natl Acad Sci USA 2007; 104: 2437-41. (Pubitemid 46391415)
33. Siebert H, Kahle PJ, Kramer ML, Isik T, Schlüter OM, Schulz-Schaeffer WJ, et al. 2010) Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain. J Neurochem 2010; 114: 1007-18.
34. Tomishige M, Stuurman N, Vale RD. Single-molecule observations of neck linker conformational changes in the kinesin motor protein. Nat Struct Mol Biol 2006; 13: 887-94. (Pubitemid 44527370)
35. Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008; 16: 1018-25. (Pubitemid 351737065)
36. Ulusoy A, Decressac M, Kirik D, Björklund A. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. [Review]. Prog Brain Res 2010; 184: 89-111.
37. Utton MA, Noble WJ, Hill JE, Anderton BH, Hanger DP. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci 2005; 118: 4645-54. (Pubitemid 41646375)